DICE News and Press, DICE Therapeutics Inc. From 10/11/22

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

The stock market has been in bear market mode throughout 2022, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) has been one of the hardest-hit stock market indexes during the rout. After seeing a new closing low for the year on Monday, investors were hoping for a respite, but the Nasd...

Top-line results from a phase 1 trial of DICE Therapeutics' ( NASDAQ: DICE ) DC-806 for psoriasis showed the candidate met its proof-of-concept goal and was biologically active . Shares are up 71% in premarket trading. Data also showed DC-806 was well tolerated...

Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an exploratory p-value of 0.0008 DC-806 was wel...

DICE Therapeutics press release ( NASDAQ: DICE ): Q2 GAAP EPS of -$0.58. Cash, cash equivalents and marketable securities totaled $282.2 million at June 30, 2022. The Company expects its current cash position to fund operations through mid-2024 and expected key clinical mi...

Completed enrollment in Phase 1 clinical trial of lead oral IL-17 antagonist DC-806; topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), ...

Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a...

HC Wainwright has initiated coverage of DICE Therapeutics ( NASDAQ: DICE ) with a buy rating lauding the company's DELSCAPE technology platform aimed at creating new therapies against "difficult to target protein-protein interactions (PPIs), using small, targeted DNA-enabling ...

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therap...

The following slide deck was published by DICE Therapeutics, Inc. in conjunction with this event. For further details see: DICE Therapeutics (DICE) Investor Presentation - Slideshow